Results 271 to 280 of about 362,523 (334)

A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment

, 2012
Giorgio V. Scagliotti, D.W. Kim, Alice T. Shaw, S-H.I. Ou, Gregory J. Riely, Scott Gettinger, Benjamin Besse, Keith D. Wilner, Yiyun Tang, Cynthia Huang Bartlett   +9 more
openalex   +1 more source

Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Are two drugs better than one in advanced NSCLC? ABSTRACT Background Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand‐1 (PD‐L1) ≥ 50% advanced non–small cell lung cancer (NSCLC).
Junipearl Cheng, Charlotte McKay, Victoria Bray, Po Yee Yip, Annette Tognela, Peey Sei Kok   +5 more
wiley   +1 more source

Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study. [PDF]

ESMO Open
Malapelle U, Nasirova F, Wang A, Cooper M, Salomonsen R, Baser E, Raiber-Moreau EA, Chuang Y, Kim YJ.   +8 more
europepmc   +1 more source

Treatment Outcomes of Concurrent Chemoradiotherapy for Locally Advanced NSCLC A Single Center Experience

openalex   +1 more source

The Current Status of Circulating Tumor DNA Utilization in Australasia: A Survey of Thoracic Oncology Group Australasia Members

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study explores the current status, utilization, and barriers to circulating tumour DNA (ctDNA) testing in thoracic oncology across Australia and New Zealand. While clinicians recognize the potential of ctDNA for guiding targeted therapy and monitoring disease, real‐world access remains inconsistent due to funding, availability, and infrastructure ...
Yifei Zhu, Danyon Lo, Deme Karikos, Malinda Itchins, Annie Wong   +4 more
wiley   +1 more source

Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions. [PDF]

Cancers (Basel)
Winter M, Jeroch J, Wetz M, Rauschendorf MA, Wild PJ.   +4 more
europepmc   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions. [PDF]

Curr Oncol
Wong AKQ, Khan SR, Hadi DK, Breadner D, Vincent MD.   +4 more
europepmc   +1 more source

Tumour progression shows decrease in PD‐L1 expression in matched metastases/primary uveal melanomas

Acta Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICI) have revolutionised the treatment of several malignancies. However, the results of ICI therapy remain unsatisfactory in metastatic uveal melanoma (UM). We analysed the expression of PD1, PD‐L1, T‐cell and macrophage markers in a set of matched primary and metastatic UM in an attempt to better ...
Maria Chiara Gelmi, Gulçin Gezgin, Ellen Kapiteijn, T. H. Khanh Vu, Martine J. Jager, Robert M. Verdijk   +5 more
wiley   +1 more source